Gynecomastia risk factors: Difference between revisions
Jump to navigation
Jump to search
Line 29: | Line 29: | ||
===Risk factors=== | ===Risk factors=== | ||
Common risk factors in the development of gynecomastia include:<ref name="pmid12765">{{cite journal| author=Wiseman EH, Chang YH, Lombardino JG| title=Piroxicam, a novel anti-inflammatory agent. | journal=Arzneimittelforschung | year= 1976 | volume= 26 | issue= 7 | pages= 1300-3 | pmid=12765 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12765 }} </ref><ref name="pmid907238">{{cite journal| author=Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH| title=Pathophysiology of spironolactone-induced gynecomastia. | journal=Ann Intern Med | year= 1977 | volume= 87 | issue= 4 | pages= 398-403 | pmid=907238 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=907238 }} </ref><ref name="pmid22862307">{{cite journal| author=Deepinder F, Braunstein GD| title=Drug-induced gynecomastia: an evidence-based review. | journal=Expert Opin Drug Saf | year= 2012 | volume= 11 | issue= 5 | pages= 779-95 | pmid=22862307 | doi=10.1517/14740338.2012.712109 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22862307 }} </ref><ref name="pmid8421478">{{cite journal| author=Braunstein GD| title=Gynecomastia. | journal=N Engl J Med | year= 1993 | volume= 328 | issue= 7 | pages= 490-5 | pmid=8421478 | doi=10.1056/NEJM199302183280708 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8421478 }} </ref><ref name="pmid18911010">{{cite journal| author=JACOBS EC| title=Gynecomastia following severe starvation. | journal=Ann Intern Med | year= 1948 | volume= 28 | issue= 4 | pages= 792-7 | pmid=18911010 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18911010 }} </ref><ref name="pmid4042075">{{cite journal| author=Tseng A, Horning SJ, Freiha FS, Resser KJ, Hannigan JF, Torti FM| title=Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. | journal=Cancer | year= 1985 | volume= 56 | issue= 10 | pages= 2534-8 | pmid=4042075 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4042075 }} </ref><ref name="pmid4042075">{{cite journal| author=Tseng A, Horning SJ, Freiha FS, Resser KJ, Hannigan JF, Torti FM| title=Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. | journal=Cancer | year= 1985 | volume= 56 | issue= 10 | pages= 2534-8 | pmid=4042075 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4042075 }} </ref><ref name="pmid1166483">{{cite journal| author=Olivo J, Gordon GG, Rafii F, Southren AL| title=Estrogen metabolism in hyperthyroidism and in cirrhosis of the liver. | journal=Steroids | year= 1975 | volume= 26 | issue= 1 | pages= 47-56 | pmid=1166483 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1166483 }} </ref><ref name="pmid5658367">{{cite journal| author=Freeman RM, Lawton RL, Fearing MO| title=Gynecomastia: an endocrinologic complication of hemodialysis. | journal=Ann Intern Med | year= 1968 | volume= 69 | issue= 1 | pages= 67-72 | pmid=5658367 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5658367 }} </ref> | |||
====Common Risk Factors==== | ====Common Risk Factors==== |
Revision as of 19:47, 10 August 2017
Gynecomastia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Gynecomastia risk factors On the Web |
American Roentgen Ray Society Images of Gynecomastia risk factors |
Risk calculators and risk factors for Gynecomastia risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]
Overview
- There are no established risk factors for [disease name].
OR
- The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
- Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
- Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.
Risk Factors
- There are no established risk factors for [disease name].
OR
- The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
- Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Common Risk Factors
- Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.
- Common risk factors in the development of [disease name] include:
- [risk factor 1]
- [risk factor 2]
- [risk factor 3]
Less Common Risk Factors
- Less common risk factors in the development of [disease name] include:
- [risk factor 1]
- [risk factor 2]
- [risk factor 3]
Risk factors
Common risk factors in the development of gynecomastia include:[1][2][3][4][5][6][6][7][8]
Common Risk Factors
- Idiopathic
- Drugs[1]
- Cirrhosis
- Starvation and Refeeding[5]
- Male hypogonadism[6]
- Testicular neoplasms[6]
- Hyperthyroidism[7]
- Chronic Kidney disease[8]
Less Common Risk Factors
- Feminizing adrenal tumors
- Ectopic hCG
- Disorders of sex development
- Familial prepubertal gynecomastia
References
- ↑ 1.0 1.1 Wiseman EH, Chang YH, Lombardino JG (1976). "Piroxicam, a novel anti-inflammatory agent". Arzneimittelforschung. 26 (7): 1300–3. PMID 12765.
- ↑ 2.0 2.1 Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH (1977). "Pathophysiology of spironolactone-induced gynecomastia". Ann Intern Med. 87 (4): 398–403. PMID 907238.
- ↑ 3.0 3.1 Deepinder F, Braunstein GD (2012). "Drug-induced gynecomastia: an evidence-based review". Expert Opin Drug Saf. 11 (5): 779–95. doi:10.1517/14740338.2012.712109. PMID 22862307.
- ↑ 4.0 4.1 Braunstein GD (1993). "Gynecomastia". N Engl J Med. 328 (7): 490–5. doi:10.1056/NEJM199302183280708. PMID 8421478.
- ↑ 5.0 5.1 JACOBS EC (1948). "Gynecomastia following severe starvation". Ann Intern Med. 28 (4): 792–7. PMID 18911010.
- ↑ 6.0 6.1 6.2 6.3 Tseng A, Horning SJ, Freiha FS, Resser KJ, Hannigan JF, Torti FM (1985). "Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications". Cancer. 56 (10): 2534–8. PMID 4042075.
- ↑ 7.0 7.1 Olivo J, Gordon GG, Rafii F, Southren AL (1975). "Estrogen metabolism in hyperthyroidism and in cirrhosis of the liver". Steroids. 26 (1): 47–56. PMID 1166483.
- ↑ 8.0 8.1 Freeman RM, Lawton RL, Fearing MO (1968). "Gynecomastia: an endocrinologic complication of hemodialysis". Ann Intern Med. 69 (1): 67–72. PMID 5658367.